GLP-2 TZ 15mg is a lyophilized dual incretin receptor agonist research peptide supplied as a single vial for controlled laboratory and analytical applications. This formulation targets both glucose dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 (GLP-1) receptors simultaneously; a dual agonist mechanism that distinguishes it from single receptor GLP-1 agonist compounds and has generated significant research interest in metabolic, endocrine, and body composition research contexts. Current inventory is limited and prioritized allocation is recommended for active research programs requiring consistent compound supply continuity.

The dual GIP and GLP-1 receptor agonism of this compound class produces a complementary mechanism of action across two distinct incretin pathways. GLP-1 receptor activation is well documented in research examining glucose dependent insulin secretion, glucagon suppression, gastric emptying delay, and appetite regulation through central nervous system satiety signaling. GIP receptor activation contributes additional insulinotropic activity and has accumulated growing research interest in studies examining adipose tissue metabolism, bone turnover, and the synergistic incretin response produced when both pathways are activated simultaneously. A combined receptor profile that has made dual incretin agonist compounds among the most actively researched peptide classes in contemporary metabolic science.

At 15mg this formulation represents a higher concentration single vial presentation suited to research protocols requiring elevated compound availability for extended experimental timelines or higher dose response evaluations. The lyophilized format preserves peptide integrity across storage and handling conditions, maintaining potency and structural stability until reconstitution. Standard practice for peptide compounds of this class where aqueous stability at ambient temperature is limited. Reconstitution with bacteriostatic water is recommended prior to use.

Every batch of CSD’s GLP-2 TZ is third party lab tested for concentration accuracy and purity prior to release, with COA documentation available on request. Canada Steroid Depot has supplied Canadian customers with consistently verified, accurately dosed research compounds for years, and our peptide range covers an expanding selection of incretin and metabolic research compounds. This formulation is currently available in limited stock, researchers sourcing this compound for active protocols should confirm availability before committing to extended research timelines. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.

Commonly researched alongside GLP-1 receptor agonist compounds in comparative incretin pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.